Published in Nature on October 26, 2015
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat Genet (2017) 2.67
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell (2016) 1.62
Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. Cancer Cell (2017) 1.39
Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol (2016) 1.15
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell (2016) 1.03
Targeting the cancer epigenome for therapy. Nat Rev Genet (2016) 1.01
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol (2016) 0.94
Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol (2016) 0.87
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol (2017) 0.81
Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016) 0.81
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Commun Signal (2017) 0.78
Regulation of T Cell Differentiation and Function by EZH2. Front Immunol (2016) 0.78
Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14. MBio (2016) 0.78
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res (2016) 0.78
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget (2016) 0.77
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget (2016) 0.76
Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunol Res (2017) 0.76
DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire. Oncotarget (2016) 0.76
Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov (2017) 0.76
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
Influences of the Gut Microbiota on DNA Methylation and Histone Modification. Dig Dis Sci (2017) 0.75
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget (2016) 0.75
The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nat Commun (2017) 0.75
Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. Nucleic Acids Res (2016) 0.75
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther (2016) 0.75
Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. Oral Oncol (2016) 0.75
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics (2016) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. J Immunother Cancer (2016) 0.75
Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. Oncoimmunology (2016) 0.75
EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res (2016) 0.75
Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma. Nat Commun (2016) 0.75
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell (2017) 0.75
Epigenetic control of the tumor microenvironment. Epigenomics (2016) 0.75
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin Epigenetics (2017) 0.75
The tumor microenvironment disarms CD8(+) T lymphocyte function via a miR-26a-EZH2 axis. Oncoimmunology (2016) 0.75
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Cancer Biol Ther (2016) 0.75
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. Trends Mol Med (2016) 0.75
Tumour immunology: Reducing silence to improve therapy. Nat Rev Immunol (2015) 0.75
Precision medicine driven by cancer systems biology. Cancer Metastasis Rev (2017) 0.75
Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol (2017) 0.75
The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer. Oncoimmunology (2017) 0.75
The role of dendritic cells in cancer. Semin Immunopathol (2016) 0.75
Interleukin-17A Promotes Lung Tumor Progression Through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol (2017) 0.75
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol (2017) 0.75
Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol (2017) 0.75
C-X-C Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways. Mol Pharmacol (2017) 0.75
Increased T cell infiltration elicited by Erk5 deletion in a Pten-deficient mouse model of prostate carcinogenesis. Cancer Res (2017) 0.75
Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment. J Clin Invest (2017) 0.75
Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun (2017) 0.75
Epigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation. Oral Dis (2016) 0.75
Targeting the epigenome in malignant pleural mesothelioma. Transl Lung Cancer Res (2017) 0.75
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology (2017) 0.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics (2000) 10.63
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature (2007) 8.32
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev (2004) 7.89
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature (2012) 4.08
Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (2000) 4.06
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med (2001) 3.81
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
The H3K27 demethylase Utx regulates somatic and germ cell epigenetic reprogramming. Nature (2012) 2.80
Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature (2012) 2.64
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity (2014) 2.08
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther (2014) 1.37
The polycomb repressive complex 2 governs life and death of peripheral T cells. Blood (2014) 0.91